Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
about
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successAdherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide studyComparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.Influence of gender on receipt of guideline-based antiretroviral therapy in the era of HAARTManagement of the metabolic effects of HIV and HIV drugs.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation ModelThe choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.Race/ethnicity and HAART initiation in a military HIV infected cohort.Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital.Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK HIV clinic.Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.
P2860
Q30979260-2CC82EF8-EE8A-45BA-92C3-466EC1542586Q35043700-D5A3E334-7E11-43BD-9DE6-5FC0D3F38FEBQ35120628-0BAFA3EE-0DF7-4172-BEC0-AB3C9CEF58BAQ35295887-C4278119-17D8-4BD0-9D65-6797DB84D555Q35316315-416CAC4E-CF89-4EBD-B9ED-9B79990C7F00Q35549179-D7A35624-530D-48D3-ADFB-90B8D526296DQ35569290-4DC0E73B-4B02-4AA2-ADA1-F349AC354C12Q36021411-32C96359-768D-4A6B-B600-9FAF5A90E125Q36079108-156EA16B-6C36-446F-A4D4-AFFDEE4FC910Q36523426-89E11EA1-9453-4E9A-A946-632EF4FA2078Q37547161-50B802D9-0423-414C-A323-625866AF68A8Q37580896-7755CC15-B362-4F9C-BCD4-CED5C3DD5783Q37692805-D7401876-7F10-48D1-BAD0-50602FC0B930Q43228891-463DA252-2DE3-489B-81DE-2501D0DA542FQ43492808-6A64CC68-862D-4D91-A38B-F7A4EA5B2BF7
P2860
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Patterns and predictors of the ...... reatment initiation in the UK.
@en
type
label
Patterns and predictors of the ...... reatment initiation in the UK.
@en
prefLabel
Patterns and predictors of the ...... reatment initiation in the UK.
@en
P2093
P1433
P1476
Patterns and predictors of the ...... treatment initiation in the UK
@en
P2093
A N Phillips
G Scullard
P J Easterbrook
P356
10.1111/J.1468-1293.2008.00512.X
P577
2008-01-01T00:00:00Z